Bio-Rad Laboratories
(BIO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 580,684 | 455,890 | 431,526 | 434,517 | 403,006 |
| Marketable Securities | 406,732 | 408,659 | 418,830 | 431,613 | 420,801 |
| Receivables | 377,904 | 391,699 | 392,443 | 381,526 | 404,091 |
| Inventories | 589,897 | 590,438 | 583,815 | 601,053 | 591,433 |
| Other current assets | 10,303 | 20,998 | 9,615 | 185,488 | 173,003 |
| TOTAL | $2,087,940 | $2,031,643 | $2,023,478 | $2,034,197 | $1,992,334 |
| Non-Current Assets | |||||
| PPE Net | 499,180 | 502,952 | 508,690 | 484,323 | 490,249 |
| Investments And Advances | 4,417,240 | 3,671,912 | 2,655,709 | 3,474,321 | 3,170,820 |
| Intangibles | 362,877 | 369,923 | 352,893 | 652,565 | 658,057 |
| Other Non-Current Assets | 279,708 | 286,484 | 70,298 | 73,256 | 74,763 |
| TOTAL | $5,559,005 | $4,831,271 | $3,587,590 | $4,684,465 | $4,393,889 |
| Total Assets | $7,646,945 | $6,862,914 | $5,611,068 | $6,718,662 | $6,386,223 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,767 | 1,757 | 493 | 1,772 | 1,721 |
| Accounts payable and accrued liabilities | 246,809 | 0 | 122,450 | 257,028 | 261,721 |
| Accrued Expenses | N/A | 239,018 | 143,510 | N/A | N/A |
| Other current liabilities | 125,952 | 127,151 | 101,218 | 149,576 | 149,394 |
| TOTAL | $445,977 | $444,306 | $450,795 | $453,159 | $442,421 |
| Non-Current Liabilities | |||||
| Long Term Debt | 437,680 | 437,606 | 438,937 | 438,803 | 438,776 |
| Deferred Revenues | N/A | N/A | 26,936 | N/A | N/A |
| Other Non-Current Liabilities | 333,038 | 336,242 | 147,766 | 172,271 | 179,174 |
| TOTAL | $1,714,158 | $1,554,753 | $1,139,942 | $1,365,022 | $1,304,856 |
| Total Liabilities | $2,160,135 | $1,999,059 | $1,590,737 | $1,818,181 | $1,747,277 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,802 | 29,820 | 29,800 | 29,962 | 29,835 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 5,184,511 | 4,585,701 | 3,722,073 | 4,550,601 | 4,281,275 |
| Other shareholders' equity | -49,305 | -80,696 | -47,087 | -32,516 | -18,927 |
| TOTAL | $5,486,810 | $4,863,855 | $4,020,331 | $4,900,481 | $4,638,946 |
| Total Liabilities And Equity | $7,646,945 | $6,862,914 | $5,611,068 | $6,718,662 | $6,386,223 |